Can you provide the last earnings date for LENZ THERAPEUTICS INC?
LENZ THERAPEUTICS INC (LENZ) last reported earnings on 11/5/2025.
NASDAQ:LENZ • US52635N1037
Past quarterly earnings results for LENZ THERAPEUTICS INC (LENZ), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | -0.59 | -0.72 | 18.10% | -55.26% | 12.5M | 6.965M | 79.47% | - |
| Q2 2025 | -0.51 | -0.62 | 18.05% | -27.50% | 5M | - | - | |
| Q1 2025 | -0.53 | -0.56 | 6.09% | 84.99% | - | - | ||
| Q4 2024 | -0.46 | -0.42 | -9.11% | 83.57% | - | - | ||
| Q3 2024 | -0.38 | -0.47 | 19.83% | 86.08% | - | - | ||
| Q2 2024 | -0.40 | -0.50 | 19.61% | 94.11% | - | - | ||
| Q1 2024 | -3.53 | -0.86 | -311.18% | -17.28% | - | - | ||
| Q4 2023 | -2.80 | -0.92 | -204.00% | 9.09% | - | - | ||
| Q3 2023 | -2.73 | -1.80 | -52.03% | 13.33% | 1.53M | -100.00% | - | |
| Q2 2023 | -6.79 | -2.19 | -209.77% | -102.08% | - | - | ||
| Q1 2023 | -3.01 | -2.37 | -27.10% | 10.42% | - | - | ||
| Q4 2022 | -3.08 | -3.52 | 12.56% | -25.71% | - | - | ||
| Q3 2022 | -3.15 | -3.28 | 3.85% | -60.71% | - | - | ||
| Q2 2022 | -3.36 | -3.51 | 4.31% | 86.09% | - | - | ||
| Q1 2022 | -3.36 | -2.78 | -20.66% | - | - | - | ||
| Q4 2021 | -2.45 | -2.12 | -15.34% | - | - | - | ||
| Q3 2021 | -1.96 | -1.98 | 0.78% | - | - | - | ||
| Q2 2021 | -24.15 | -7.89 | -206.10% | - | - | - | ||
| Q1 2021 | - | - | - | - | ||||
| Q4 2020 | - | - | - | - | ||||
| Q3 2020 | - | - | - | - | ||||
| Q2 2020 | - | - | - | - | ||||
| Q1 2020 | - | - | - | - |
Notes
LENZ THERAPEUTICS INC (LENZ) last reported earnings on 11/5/2025.
LENZ THERAPEUTICS INC (LENZ) beat EPS estimates and beat revenue estimates in the most recent quarter.
In the last 4 quarters, LENZ THERAPEUTICS INC (LENZ) has beaten EPS estimates in 3 out of 4 releases.